Inhibitor Therapeutics, Inc.
OTCPKInhibitor Therapeutics heads into the final days of April with a quietly unusual setup: short interest has collapsed to near-zero, yet the cost to borrow has more than doubled over the past year — a combination that tells its own story about a thinly traded OTC biotech. The dominant move over the past month has been a sharp retreat from short sellers. Estimated short interest fell…
Snapshot as of 10 May 2026
Inhibitor Therapeutics heads into the final days of April with a quietly unusual setup: short interest has collapsed to near-zero, yet the cost to borrow has more than doubled over the past year — a combination that…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for INTI — free to start on ORTEX.
Sign up for free →Open INTI on ORTEX